Information session: Targeting the potential of PSMA

Emerging evidence on the role of prostate-specific membrane antigen in the development and growth of prostate cancer has revolutionised treatment of the disease, delivering major breakthroughs and saving many lives.
While high rates of screening mean many men are diagnosed and treated before prostate cancer has spread, around 15% of Australian men are diagnosed with advanced forms of the disease that are incurable.
We partnered with Telix for this information session to hear about targeted nuclear medicine therapy and a new clinical trial to evaluate the effectiveness of PSMA targeted therapy at different stages of prostate cancer, from recurrence to advanced metastatic disease.
Host Matt Britland, Managing Director, MedWise, is joined by panellists A/Prof Sze Ting Lee, President of the Association of Nuclear Medicine Specialists and Nuclear Medicine Specialist at Austin Health; and Prof Nat Lenzo, Group Clinical Director of Theranostics & Nuclear Medicine Physician, GenesisCare. Full bios available via the PCFA Online Community at onlinecommunity.pcfa.org.au/
Call 1800 22 00 99 or go to www.pcfa.org.au/support/prostate-cancer-specialist-nurses/ for information and support.
Proudly sponsored by Telix & MedWise.

[@Armando-nj1pm]

'promosm'